The NJ DOH Has Removed the Medicinal Marijuana Program RFA Previously Published on June 3, 2019
The New Jersey Department of Health (DOH) still plans to seek applications for new Alternative Treatments Centers (ATCs) beginning in July 2019. However, it has removed the Request for Applications (RFA) previously published on June 3, 2019. According to a statement on the DOH website, an amended Request for Applications will be posted on July 1, 2019.
Gov. Murphy and Legislature Reach Compromise
As discussed in greater detail in prior articles, both the New Jersey Legislature and Gov. Phil Murphy want to expand the New Jersey Medicinal Marijuana Program. On June 3, the DOH issued a Request for Applications seeking new applicants to operate up to 108 additional ATCs, including up to 24 cultivation endorsements, up to 30 manufacturing endorsements, and up to 54 dispensary endorsements.
The New Jersey Legislature subsequently introduced and passed Assembly Bill 20/Senate Bill 20, which reflects a compromise between Gov. Murphy and the Legislature on key issues. Notably, it transfers medical marijuana oversight from the Department of Health’s jurisdiction to a new five-member Cannabis Regulatory Commission, a move that Gov. Murphy has opposed. It also caps the total number of entities authorized to cultivate medical cannabis at 28 for the first 18 months after the effective date of the bill, which is higher than limits established in prior medical marijuana legislation but less than the recent RFA.
A20 includes several provisions that exempt RFAs published prior to the effective date of the bill. The restriction on vertical integration will not apply to up to four ATCs issued permits after the effective date of the bill pursuant to a request for applications published in the New Jersey Register prior to the effective date of the bill, which will be deemed to hold medical cannabis cultivator, medical cannabis manufacturer, and medical cannabis dispensary permits. In addition, applications submitted pursuant to a previously published RFA will not be subject to the bill’s new application criteria.
New RFA in the Works
Given the exemptions for existing RFAs, it makes sense that Gov. Murphy has yet to sign A20 and is moving quickly to publish a new RFA on July 1. The exact details of the new RFA have yet to be released. However, it is likely that the number of licenses will be less than 108.
The Scarinci Hollenbeck Cannabis Law Group will post an update once the RFA is released. In the meantime, entities that are interested in entering the New Jersey medical cannabis industry can still start your preparations. There are numerous legal, logistical and operational issues that must be addressed, and time is of the essence.
If you have any questions, please contact us
If you have any questions or if you would like to discuss the matter further, please contact me, Dan McKillop, at 201-806-3364.
This article is a part of a series pertaining to cannabis legalization in New Jersey and the United States at large. Prior articles in this series are below:
Disclaimer: Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy. Legal advice provided by Scarinci Hollenbeck, LLC is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Scarinci Hollenbeck, LLC will not provide assistance in circumventing Federal or state cannabis law or policy, and advice provided by our office should not be construed as such.
IP Infringement: What Steps Can You Take If You're Affected?
IP infringement occurs when someone uses your intellectual property without your permission or beyond the scope of the permission you granted. Common examples of IP infringement include copying a product’s patented features or using a trademarked logo in a way that is likely to confuse consumers about the source or affiliation of goods or services. […]
Public Allegations, Unfinished Investigation: What New Jersey Businesses Should Do Next
When facing public allegations of wrongdoing, companies should not let the speed of the public conversation dictate the speed of an investigation. An investigation designed to confirm a preferred narrative rather than establish the facts can create serious problems later, particularly if litigation, regulatory scrutiny, or employment claims follow. Key Takeaways When public allegations surface […]
BESS Interconnection: Managing Grid, Cost, and Schedule Risk
For battery energy storage system (BESS) developers, securing equipment and site control is only part of the development equation. A project must also connect to the electric grid, and increasingly, BESS interconnection is one of the biggest sources of schedule, cost, and contractual risk. Key Takeaways This article is Part 3 of our Battery Storage […]
Navigating Director and Officer Liability in Times of Financial Distress
Director and officer liability increases sharply when a company is in financial distress. Decisions that would draw little attention in a healthy business can later be challenged by creditors, shareholders, bankruptcy trustees, and regulators as breaches of fiduciary duty, fraudulent transfers, or oversight failures. Understanding where that exposure comes from, and how to manage it, […]
Before You Buy: Managing Real Estate and Permitting Risk for BESS Projects in New York and New Jersey
For developers pursuing battery energy storage system (BESS) projects, finding the right property is only the beginning. BESS site selection is as much a legal and transactional exercise as a real estate decision, with risk analysis central to the project’s ultimate success. Key Takeaways The core questions for BESS site selection in New York and […]
What Business Owners Get Wrong Before Meeting a Litigation Attorney
What should you expect when meeting a litigation attorney about a business dispute? You should expect to describe the dispute in your own words, hand over the most important documents, flag any deadlines or immediate threats, and leave with a clearer picture of the problem, what information is still needed, and the likely next steps. […]
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Sign up to get the latest from our attorneys!
Explore What Matters Most to You.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!
